INFI - Infinity Pharma's eganelisib Fast Track'd in U.S. for breast cancer

Infinity Pharmaceuticals (INFI) shares jumped 19% in premarket, in reaction to FDA's Fast Track review tag for its eganelisib (IPI-549) in combination with a checkpoint inhibitor and chemotherapy, for the treatment of inoperable locally advanced or metastatic triple-negative breast cancer ((TNBC)), in the first-line setting.Infinity is currently enrolling patients in MARIO-3, the Company’s ongoing Phase 2 study in collaboration with Roche/Genentech to evaluate eganelisib in a triple combination front-line regimen with Tecentriq and Abraxane in TNBC.Earlier this year, the company also received Fast Track designation for eganelisib in combination with the checkpoint inhibitor Opdivo for the treatment of advanced urothelial cancer.

For further details see:

Infinity Pharma's eganelisib Fast Track'd in U.S. for breast cancer